Careers

Diversity

With 17 offices, from New York to Los Angeles and Seattle to Orlando, we live and work in communities all over the U.S., collaborating across locations, disciplines and even borders. Our experienced, highly ranked lawyers serve businesses wherever they are and wherever they want to go.

Offices

About Us

Pages

Professionals

Thought leadership: blogs, podcasts, videos, publications, events and news

Insights

Services

Pro Bono

Am Law 100 firm with practices in Business, Digital Assets and Data Management, Intellectual Property, Labor & Employment, Litigation and Tax.

Home | BakerHostetler

Helping physicians complete new training for DEA compliance in opioid prescribing

Another Minimum Wage Increase on the Horizon for Federal Contractors

A look at civil rights cases to be heard by the Supreme Court this term

BakerHostetler attorneys plan, present at NYSBA International Section global conference

Partner William Bergmann authored an “Expert Analysis” published on May 13, 2021, by Law360. The article “COVID IP Waiver Doesn’t Resolve Vaccine Production Barriers” examines proposed waivers for some intellectual property protections related to COVID-19 treatments, including vaccines.  Bergmann’s article explores the ramifications of such waivers, examines how they might be implemented, and notes that the “know-how needed to develop vaccines and the accompanying infrastructure are much bigger barriers to their production” than the proprietary platforms that allowed the vaccine development.  He concludes that “there is a significant chance that the current global supply will exceed the demand for doses long before any developing countries actually begin production.”  <a href="https://www.law360.com/environmental/articles/1383618/covid-ip-waiver-doesn-t-resolve-vaccine-production-barriers-">Read the article (registration required)</a>.

William Bergman Article Examines Calls for COVID IP Waivers

Featured Insights

Related Services

Featured Insights